BeiGene (ONC) has received FDA approval for Tevimbra for first-line esophageal cancer with chemo. Read more here.

BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development ...

For the quarter ended December 2024, BeiGene, Ltd. (ONC) reported revenue of $1.13 billion, up 77.8% over the same period last year. EPS came in at -$1.43, compared to -$3.53 in the year-ago quarter.

Beigene, Ltd. (NASDAQ:ONC – Get Free Report)’s stock price gapped down prior to trading on Monday following insider selling activity. The stock had previously closed at $271.80, but opened at $255.83.

Bank of America upgraded shares of Beigene (NASDAQ:ONC – Free Report) from a neutral rating to a buy rating in a report published on Monday morning, MarketBeat.com reports. The brokerage currently has ...

Below is Validea's guru fundamental report for BEIGENE LTD (ADR) (ONC). Of the 22 guru strategies we follow, ONC rates highest using our P/B Growth Investor model based on the published strategy ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

It's been a good week for BeiGene, Ltd. ( NASDAQ:ONC ) shareholders, because the company has just released its ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...

Sino American biotech BeiGene has announced financial results and corporate updates from the fourth quarter and full year ...